GUILFORD, Conn.--(BUSINESS WIRE)--October 30, 2025--
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain--the Swoop$(R)$ system--today announced that it will report full financial results for the third quarter 2025 on Thursday, November 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.
For more information about the Swoop(R) system, please visit HyperfineMRI.com.
About the Swoop(R) Portable MRI Systems
The Swoop(R) Portable MR Imaging(R) Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop(R) system--the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop(R) system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030393825/en/
CONTACT: Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io
Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
(END) Dow Jones Newswires
October 30, 2025 16:58 ET (20:58 GMT)
Comments